Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04117958 · ClinicalTrials.gov registry record · Phase 1
Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT04117958 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 58 participants.
The verdict
NCT04117958, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of AMG 199 in adult subjects and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
Interventions
- DRUG AMG 199
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2020-01-20 |
| Est. Completion | 2023-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04117958
The ClinicalTrials.gov registry entry for NCT04117958 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 199 is the first listed.
NCT04117958 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04117958 about?
NCT04117958 is a clinical study titled "Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers". To evaluate the safety and tolerability of AMG 199 in adult subjects and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
What is the current status of trial NCT04117958?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2020-01-20. Estimated completion is 2023-06-01.
What interventions are being tested in trial NCT04117958?
The interventions under investigation include: AMG 199 (DRUG).
Who is sponsoring clinical trial NCT04117958?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.